MGIT sensitivity testing and genotyping of drug resistant Mycobacterium tuberculosis isolates from Mizoram, Northeast India

Sailo, Christine Vanlalbiakdiki; Zami, Zothan; Lalremruata, Ralte; Sanga, Zothan; Fela, Vanlal; Kharkongor, Febiola; Chhakchhuak, Lily; Chhakchhuak, Zothankhuma; Laldinmawii, Gracy; Kumar, Dhiraj; Kumar, Nachimuthu Senthil

doi:10.1016/j.ijmmb.2022.06.003

Cited by 3 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies had mostly reported the mutations observed for probe E as S531L [30] , [32] , probe B as D516V and D516Y and probe C as S522L [33] . Our previous sanger sequencing study from Mizoram reported the mutation at probe A region as L511P and probe D region as H526Q and H526L [34] . This study also reports high number of RR-TB detected using cycle threshold > 4 cycles (all probe positive RR-TB).…”

Section: Discussionmentioning

confidence: 99%

Distribution and frequency of common mutations in rpoB gene of Mycobacterium tuberculosis detected by Xpert MTB/RIF and identification of residential areas of rifampicin resistant-TB cases: A first retrospective study from Mizoram, Northeast India

Sailo

Lalremruata

Sanga³

et al. 2022

Journal of Clinical Tuberculosis and Other Mycobacterial Diseas

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Distribution and frequency of common mutations in rpoB gene of Mycobacterium tuberculosis detected by Xpert MTB/RIF and identification of residential areas of rifampicin resistant-TB cases: A first retrospective study from Mizoram, Northeast India

Sailo

Lalremruata

Sanga³

et al. 2022

Journal of Clinical Tuberculosis and Other Mycobacterial Diseas

Self Cite

View full text Add to dashboard Cite

“…Rifampicin binds to the RNA polymerase, inhibiting transcription. Using such combined therapies is curative and reduces the risk of relapse but increases the likelihood of drug-resistant strains. , As the health system’s quality varies from person to person, the prevalence of drug-resistant strains of Mycobacterium tuberculosis increases globally, thereby increasing the difficulty of treating TB (WHO, 2016) . There are several different mechanisms that Mycobacterium tuberculosis utilizes to develop drug resistance such as cell-wall impermeability, efflux-pumps, drug-degradation and modification, target-alteration, and target-mimicry (Figure ).…”

Section: Mechanism Of Antimicrobial Resistance In Mycobacterium Tuber...mentioning

confidence: 99%

Overcoming Mycobacterium tuberculosis Drug Resistance: Novel Medications and Repositioning Strategies

Sachan,

Mistry,

Dholaria

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Mycobacterium tuberculosis, the bacterium responsible for tuberculosis, is a global health concern, affecting millions worldwide. This bacterium has earned a reputation as a formidable adversary due to its multidrug-resistant nature, allowing it to withstand many antibiotics. The development of this drug resistance in Mycobacterium tuberculosis is attributed to innate and acquired mechanisms. In the past, rifampin was considered a potent medication for treating tuberculosis infections. However, the rapid development of resistance to this drug by the bacterium underscores the pressing need for new therapeutic agents. Fortunately, several other medications previously overlooked for tuberculosis treatment are already available in the market. Moreover, several innovative drugs are under clinical investigation, offering hope for more effective treatments. To enhance the effectiveness of these drugs, it is recommended that researchers concentrate on identifying unique target sites within the bacterium during the drug development process. This strategy could potentially circumvent the issues presented by Mycobacterium drug resistance. This review primarily focuses on the characteristics of novel drug resistance mechanisms in Mycobacterium tuberculosis. It also discusses potential medications being repositioned or sourced from novel origins. The ultimate objective of this review is to discover efficacious treatments for tuberculosis that can successfully tackle the hurdles posed by Mycobacterium drug resistance.

show abstract

“…Tuberculosis is caused by Mycobacterium tuberculosis (Mtb), which is made up of pathogens that can live in both humans and animals [1]. Even though a lot of work has been done over the past 20 years to make new vaccines, drugs, and diagnostics, tuberculosis is still a global emergency.…”

Section: Introductionmentioning

confidence: 99%

Development of Mouse Monoclonal Antibody Anti-Ag85B Protein of Mycobacterium tuberculosis

Pambudi¹,

Widayanti²,

Ningsih³

et al. 2023

Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022)

View full text Add to dashboard Cite

One of the abundant biomarkers in tuberculosis (TB) infected human serum is the Ag85B antigen. The quest for protein biomarkers has been conducted to develop a diagnostic kit and vaccine for TB. Numerous studies have demonstrated that the development of monoclonal antibodies (mAbs) that recognize a specific repertoire of Mycobacterium tuberculosis antigens and the tests based on monoclonal antibodies have proved helpful in TB detection. Unfortunately, numerous mAbs currently used for TB serodiagnosis were generated elsewhere. Improving the ability to produce mouse monoclonal antibodies, specifically against Ag85B, is imperative as Indonesia is the second prevalent TB country. Therefore, a synthetic plasmid expressing Ag85B-HA fusion protein was expressed in the mammalian system. The expression of Ag85B protein in the 293T cells lysates was confirmed by western blot analysis. A specific protein band around 36 kDa appeared against antibody anti-HA. The lysate of recombinant mammalian cells was used as an inducer to generate B-cells expressing mouse monoclonal antibodies anti-Ag85B. By fusing 'PAI' mouse myeloma cells and Bcells from immunized mice, hybridoma mAb-producing cells were obtained. As many as 43 hybridomas cells were tested against recombinant Ag85B antigen by immunofluorescence assay (IFA). We found two (2) hybridomas cells specifically secreting monoclonal antibody anti-Ag85B. One hybridoma, 3C12 clone, was confirmed to have the ability to recognize Ag85B protein validated by western blot analysis. Similar to previous research, our western blot analysis shows that our monoclonal antibody can identify the antigen Ag85 at a protein size of around 30 kDa. Further analysis and characterization should be conducted to explore the potency of those monoclonal antibodies for developing TB diagnostic kits.

show abstract

MGIT sensitivity testing and genotyping of drug resistant Mycobacterium tuberculosis isolates from Mizoram, Northeast India

Cited by 3 publications

References 25 publications

Distribution and frequency of common mutations in rpoB gene of Mycobacterium tuberculosis detected by Xpert MTB/RIF and identification of residential areas of rifampicin resistant-TB cases: A first retrospective study from Mizoram, Northeast India

Distribution and frequency of common mutations in rpoB gene of Mycobacterium tuberculosis detected by Xpert MTB/RIF and identification of residential areas of rifampicin resistant-TB cases: A first retrospective study from Mizoram, Northeast India

Overcoming Mycobacterium tuberculosis Drug Resistance: Novel Medications and Repositioning Strategies

Development of Mouse Monoclonal Antibody Anti-Ag85B Protein of Mycobacterium tuberculosis

Contact Info

Product

Resources

About